May 9th 2024
In an interview with Targeted Oncology, Shilpa Gupta, MD, discussed the rationale and potential significance of the MAIN-CAV trial in patients with locally advanced/metastatic urothelial carcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Pembrolizumab Granted Priority Review in Second-Line Bladder Cancer
February 4th 2017A supplemental Biologics License Application for pembrolizumab has been granted a priority review by the FDA for the treatment of patients with locally advanced or metastatic urothelial cancer who progress following platinum-containing chemotherapy.
Read More
Nivolumab Approved by the FDA for Urothelial Carcinoma
February 3rd 2017Nivolumab has been granted an accelerated approval by the FDA as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy, based on findings from a phase II CheckMate-275 study.
Read More
Study Results Support Pembrolizumab as Second-Line Standard of Care in Urothelial Carcinoma
February 2nd 2017Treatment with the PD-1 inhibitor pembrolizumab significantly prolonged overall survival over investigators’ choice of chemotherapy in patients with recurrent advanced urothelial carcinoma.
Read More
Atezolizumab Granted Priority Review by FDA for Second Bladder Cancer Indication
January 10th 2017A supplemental new drug application for the PD-L1 inhibitor atezolizumab has been granted priority review by the FDA in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma as a frontline therapy or following progression occurring ≥12 months after neoadjuvant or adjuvant chemotherapy.
Read More
Durvalumab Granted Priority Review by FDA for Bladder Cancer
December 30th 2016The FDA has granted a priority review to a biologics license application for durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed on standard platinum‑based chemotherapy.
Read More
More Research Needed Before Immunotherapy Trumps Chemo in Firstline Bladder Cancer Care
December 30th 2016Gopa Iyer, MD, discusses the standard chemotherapy options available for patients with bladder cancer, the ongoing progress with immunotherapy, and the management of immune-related toxicities.
Read More
Chemo Still a Mainstay in Bladder Cancer Care, Despite Promise of Immunotherapies
December 30th 2016Dean Bajorin, MD, discusses the ongoing studies exploring new chemotherapy approaches in these patients and how the cytotoxic treatments could still ultimately be replaced with immuno-oncology agents.
Read More
Impact of the KEYNOTE-045 Study Comparing Pembrolizumab and Chemotherapy in Bladder Cancer
November 17th 2016Joaquim Bellmunt, MD, PhD, attending physician of Solid Tumor Oncology at Dana-Farber Cancer Institute, discusses the impact of the phase III KEYNOTE-045 study, which compared second- or third-line pembrolizumab with investigator-choice chemotherapy as a treatment for patients with metastatic or locally advanced, unresectable urothelial carcinoma. All patients in the study had recurred or progressed following platinum-based chemotherapy.
Watch
PD-1/CTLA-4 Inhibitor Combination Highly Effective for Metastatic Bladder Cancer
November 15th 2016Treatment with the combination of nivolumab and ipilimumab at selected doses led to a high response rate and marked improvements in overall survival for patients with pretreated metastatic urothelial carcinoma.
Read More
Molecular Profiling on the Uptake for Increased Targeted Therapies in Bladder Cancer
November 3rd 2016The recommendation for molecular testing made in the second revision of the 2016 guidelines on bladder cancer from the National Comprehensive Cancer Network (NCCN) could make a considerable difference in increasing the amount of trials and targeted therapies in the long run for subtypes of patients with bladder cancer.
Read More
Pembrolizumab Demonstrates Antitumor Activity in Phase II Bladder Cancer Study
November 1st 2016Early results from a pre-planned interim analysis in the KEYNOTE-052 phase II trial of first-line pembrolizumab in cisplatin-ineligible patients with metastatic urothelial cancer demonstrated antitumor activity.
Read More
Results of a First-Line Study of Pembrolizumab in Advanced Urothelial Cancer
October 25th 2016Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the results of a recent first-line study of pembrolizumab in advanced urothelial cancer.
Watch
The Rationale Behind CheckMate-275 in Metastatic Bladder Cancer
October 11th 2016Matthew Galsky, MD, professor of Medicine, Mount Sinai School of Medicine, discusses the significant findings in, and the rationale behind conducting the CheckMate-275 trial during an interview at the 2016 ESMO Congress.
Watch
Results of Phase II mUC Trial Support Approval of Nivolumab Applications
October 11th 2016Safety, efficacy, and biomarker results from the phase II CheckMate-275 trial of the PD-1 inhibitor nivolumab (Opdivo) that support FDA and European Medicines Agency (EMA) applications were reported at the 2016 ESMO Congress.
Read More
FDA Panel Votes 14-0 Against Approval of Apaziquone for Bladder Cancer
October 5th 2016In a 14-0 vote, the FDA’s Oncologic Drugs Advisory Committee (ODAC) denied the approval of apaziquone (EOquin; Qapzola) for intravesical instillation immediately following transurethral resection in patients with non-muscle invasive bladder cancer.
Read More
EMA Validation Puts Nivolumab Under Formal Review for Bladder Cancer
October 5th 2016A type II variation application for the use of nivolumab (Opdivo) as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma (mUC) who have progressed following platinum-based chemotherapy is now under formal review.
Read More